Achilles Therapeutics shares are trading lower after the company reported Q4 financial results. The company announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.
Portfolio Pulse from Benzinga Newsdesk
Achilles Therapeutics' shares dropped following the announcement of Q4 financial results and interim Phase I/IIa data from the CHIRON and THETIS studies on advanced cancers.
April 04, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Achilles Therapeutics' stock price declined after reporting Q4 financials and interim data from cancer studies.
The decline in Achilles Therapeutics' stock price is directly related to the announcement of its Q4 financial results and the interim data from its cancer studies. Financial results often impact stock prices, and the interim data, while early, may have not met investor expectations, leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100